Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (5y) (2014 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.39 Bn | 620.63 Bn | 17.26 Bn |
| 2 | AbbVie | 445.66 Bn | 439.09 Bn | 12.70 Bn |
| 3 | Merck | 357.45 Bn | 350.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.58 Bn | 259.89 Bn | 11.24 Bn |
| 5 | Pfizer | 156.75 Bn | 145.05 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.28 Bn | 18.62 Bn | 683.80 Mn |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.79% |
| Mar 31, 2026 | 7.69% |
| Dec 31, 2025 | 16.22% |
| Sep 30, 2025 | 5.32% |
| Jun 30, 2025 | 82.51% |
| Mar 31, 2025 | 41.00% |
| Dec 31, 2024 | 15.55% |
| Sep 30, 2024 | -6.47% |
| Jun 30, 2024 | -1.14% |
| Mar 31, 2024 | -50.06% |
| Dec 31, 2023 | 3.73% |
| Sep 30, 2023 | -4.30% |
| Jun 30, 2023 | 33.51% |
| Mar 31, 2023 | 3.36% |
| Dec 31, 2022 | 21.72% |
| Sep 30, 2022 | 7.62% |
| Jun 30, 2022 | 3.62% |
| Mar 31, 2022 | -8.22% |
| Dec 31, 2021 | 14.72% |
| Sep 30, 2021 | -0.77% |